May 6 (Reuters) - Laboratorios Farmaceuticos ROVI SA ROVI.MC:
Q1 OPERATING REVENUE 152.5 MILLION EUROS
Q1 EBITDA 20.3 MILLION EUROS
Q1 NET PROFIT 9.4 MILLION EUROS
EXPECTS ITS 2026 OPERATING REVENUE TO CONTINUE TO INCREASE COMPARED TO 2025, ALTHOUGH BY A LOW- TO MID-SINGLE-DIGIT PERCENTAGE
THIS IS MORE MODERATE GROWTH SCENARIO FOR 2026 THAN PREVIOUSLY ANNOUNCED AND IS SUBJECT TO VARIOUS FACTORS
Source text
Further company coverage: ROVI.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 567 69 66 00;))